EBITDA: Income before interest, taxes, depreciation and amortization.
Rein Therapeutics Inc. (RNTX) had EBITDA of $-5.61M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.50M |
|
-- |
|
-- |
|
$5.61M |
|
$-5.61M |
|
$0.11M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.61M |
|
|
EBITDA |
$-5.61M |
21.92M |
|
21.92M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$8.33M |
|
$0.00M |
|
$49.30M |
|
$57.63M |
|
$5.98M |
|
-- |
|
$46.78M |
|
$52.75M |
|
$4.87M |
|
$-43.66M |
|
$4.87M |
|
22.00M |
|
| Cash Flow Statement Financials | |
$-6.17M |
|
-- |
|
$0.74M |
|
$12.87M |
|
$7.43M |
|
$-5.44M |
|
$0.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-112.86% |
|
12.60% |
|
-9.55% |
|
-112.86% |
|
$0.22 |
|
$-0.28 |
|
$-0.28 |
|